US Patent

US8202537 — Modified release formulations containing drug-ion exchange resin complexes

Formulation · Assigned to Tris Pharma Inc · Expires 2027-03-15 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid dose composition containing a mixture of two types of methylphenidate-ion exchange resin complexes with modified release coatings.

USPTO Abstract

A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured.

Drugs covered by this patent

Patent Metadata

Patent number
US8202537
Jurisdiction
US
Classification
Formulation
Expires
2027-03-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Tris Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.